Category
ADC Therapy Antibody Therapy Cell & Gene Therapy Oncolytic Virotherapy Others Protein Therapy Small Molecule Vaccine
2025/12/18Flyer Small Molecule
PARP inhibitors are currently in the preclinical development stage, aiming to address the challenges of systemic toxicity and limited blood-brain barrier (BBB) penetration.
Protheragen's business is growing rapidly after founded in New York. Our business has evolved from the initial intermediary service to encompass segments in equity investment and program incubation.
 |
Protheragen Inc. |
 |
Quick Links |